Align Technology (ALGN) 2025 Conference June 04, 2025 08:10 AM ET Speaker0 Alright. Good morning, everyone. My name is Mike Sarcone. I'm an analyst on the US Medical Supplies and Devices team and welcome to day one of Jefferies twenty twenty five New York Healthcare Conference. This is a track for Align Technologies and from the company, we've got Simon Beard, EVP and managing director for the EMEA region, also joined by Shirley Stacy who's VP finance Corporate Communications and Investor Relations, and we ...

IDEAYA Biosciences (IDYA) 2025 Conference June 04, 2025 08:10 AM ET Speaker0 Hi everyone. My name is Maury Raycroft and one of the biotech analysts at Jefferies. So it's a great pleasure that I'd like to welcome the IDEA team. We've got Yajiro Hata, CEO, and Josh Blaharski, the CFO. Thanks so much for joining us today. Speaker1 Great. Thanks so much Maury and thank you to Jeffries for the opportunity to participate this year and Josh and I will be talking today. Thanks again. Speaker0 And we're going do fir ...

Varex Imaging (VREX) 2025 Conference June 04, 2025 08:10 AM ET Speaker0 The med tech analyst at Jefferies. Thanks for coming to our conference. I'm very excited to have management from Verix Imaging here as well. So to my immediate left, you got Sany Sanyal, the CEO, and next to him, the CFO, Sam Maheshwari. Thank you gentlemen for coming, and I'm looking forward to a good discussion. I guess to start, maybe a little bit high level. So, you know, you guys are leaders in CT and x-ray tubes and detectors. You ...

Summary of Ardelyx (ARDX) Conference Call Company Overview - Ardelyx has experienced significant fluctuations over the past few years, particularly since 2021 when it launched Ibsrela after overcoming a Complete Response Letter (CRL) from the FDA regarding Exposa [3][4] - The company currently markets two products: Ibsrela for IBS-C and Exposa for dialysis patients with hyperphosphatemia [4][5] Financial Guidance and Performance - Ardelyx reaffirmed its revenue guidance for Ibsrela at $240 million to $250 million for the current year [5][12] - The company noted that the IBS-C market has been growing at double digits for the past three to four years, with 50,000 new patients starting therapy for GCC agonists each month [8][9] - The company aims for Ibsrela to reach peak sales of $1 billion, with the potential to achieve this sooner than the previously projected timeline of 2033 [18][19] Market Dynamics - The first quarter typically sees a contraction in the IBS-C market due to insurance policy resets, which affects patient access and spending [7][8] - Despite the contraction, Ibsrela continues to gain traction, with positive feedback from physicians regarding its efficacy compared to GCC agonists [13][14] - The company is exploring additional indications for Ibsrela, such as Chronic Idiopathic Constipation (CIC), which has a larger patient population compared to IBS-C [24][28] Exposa Performance and Strategy - Exposa generated $25 million in revenue in Q1, with the company focusing on maintaining patient access rather than reimbursement issues [29][30] - The decision not to participate in the TDAPA process was made to ensure non-Medicare patients have access to Exposa, despite losing 60% of the total addressable market (TAM) due to changes in Medicare coverage [30][37] - The company is optimistic about Exposa's growth potential, targeting peak sales of $750 million by penetrating 30% of the 220,000 patients in the market [34][58] Regulatory and Legal Considerations - Ardelyx is currently appealing a CMS decision that classifies Exposa as a renal dialysis service, which could restore access for a significant portion of patients [53][57] - A favorable outcome from the appeal could increase the patient base by 60%, significantly impacting revenue potential [59][60] Business Development and Future Outlook - Ardelyx is actively seeking business development opportunities to expand its product portfolio, focusing on both GI and renal markets [63] - The company aims to build a sustainable enterprise by identifying and acquiring products that align with its strategic goals [64] Key Takeaways - Ardelyx is positioned for growth with its two commercial products, Ibsrela and Exposa, despite facing market challenges and regulatory hurdles - The company is optimistic about achieving its financial targets and expanding its market presence through strategic initiatives and potential new indications for its products

Praxis Precision Medicines (PRAX) 2025 Conference June 04, 2025 08:10 AM ET Speaker0 Good morning everyone. Welcome to the Jefferies Global Healthcare Conference twenty twenty five. With me today I have the great pleasure of introducing Praxis Precision Medicine's CEO and dear friend Marcio Souza. Marcio, how are you doing this morning? Speaker1 Doing great. Living the dream. Speaker0 Amazing. Well, we'll just jump right into it because there's so much exciting work you guys are doing at Praxis. Top of mind ...

Annexon (ANNX) 2025 Conference June 04, 2025 08:10 AM ET Speaker0 My name is Andrew Tsai, senior biotech analyst at Jefferies. Thanks for coming to our day one of the June Healthcare Conference. And it's my pleasure to have to my right Doug Love, CEO of Inexon. Welcome, Doug. Speaker1 Thank you. Speaker0 And maybe to start, give us an introduction about Inexon briefly. I do have a lot of questions for you. But what are you trying to achieve? And just walk us briefly through your milestones over the next six ...

Generation Bio (GBIO) 2025 Conference June 04, 2025 08:10 AM ET Speaker0 Good morning, everyone. I'm Farzin Hak, one of the biotech analysts at Jefferies. It's my pleasure to introduce Jeff McDonough, CEO of Generation Bio. He's going to talk about an exciting way to deliver siRNA to T cells for development of that approach for the treatment of autoimmune diseases. Welcome Jeff. Speaker1 Farzin, thank you and good morning everybody. It's really a pleasure to be here. Really appreciate the invitation to spea ...

Spyre Therapeutics Inc (SYRE) 2025 Conference June 04, 2025 08:10 AM ET Speaker0 Alrighty. Good morning, everyone. Really appreciate you joining us. My name is Akash Jawari. I am a pharma and biotech analyst here at Jefferies and this is day one of our wonderful New York Healthcare Conference. I've got Cameron from Spire. Cameron, why don't I hand it off to you for some brief introductory remarks and then we'll get started with the Q and A. Speaker1 Sounds good. Thanks for having me as always. So the the br ...

Uniti Group (UNIT) 2025 Conference June 04, 2025 08:00 AM ET Speaker0 Alright. Let's get started. Good morning. Welcome to the Wednesday morning session of NAREIT REIT week twenty twenty five. My name is Greg Williams. I cover cable, wireless and telco as well as fiber at TD Cowen. I'm joined in this session by the President and CEO of Unity, Kenny Gunderman. Kenny, thanks for joining us. Speaker1 Greg, good morning. It's good to be here. Speaker0 Maybe we could just start with finishing off the quarter in ...

Pharvaris (PHVS) Update / Briefing June 04, 2025 08:00 AM ET Speaker0 Good morning, and welcome to the Farvaris event. At this time, all attendees are in a listen only mode. A question and answer session will follow the formal presentations. As a reminder, this call is being recorded, and a replay will be made available on the Farvaris website following the conclusion of the event. I'd now like to turn the call over to Maggie Beller, Head Head of Corporate and Investor Communications at Farvaris. Please go ...